Effect of low dose epinephrine injection in reducing surgical complications in patients undergoing surgery for benign prostate enlargement.

Efficacy of Low Dose Intravenous Epinephrine Infusion in Improving Perioperative Outcomes in Patients Undergoing Transurethral Resection of Prostate - A Prospective Parallel Arm Double Blinded Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036964

Enrollment

Registered

2021-09-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: low dose intravenous epinephrine infusion: Patients will be administered intravenous epinephrine (1mg of epinephrine in 100ml normal saline) at a rate of 0.05 Î¼g/ kg/ min throughout th

Eligibility

Inclusion criteria

Inclusion criteria: Patients with benign prostatic hyperplasia with any one of the following: 1. Lower urinary tract symptoms who had failed standard medical therapy (alpha blockers, 5 alpha reductase inhibitors) 2. Recurrent urinary retention (drug-refractory) 3. Recurrent urinary tract infection 4. Recurrent hematuria

Exclusion criteria

Exclusion criteria: ASA Grade 3 or more. 1. Patients with congenital or acquired Hyper/ hypo coagulation disorders. 2. Patients with hematological malignancies. 3. Patients with decompensated chronic liver disease or renal impairment or other bleeding diathesis. 4. Patients with collagen vascular disease or other connective tissue disorders. 5. Patients with a history of thromboembolic disease. 6. Patients with history of arrhythmias 7. Patients with a history of acute coronary syndrome within the past 12 months 8. Patients with pheochromocytoma, thyrotoxicosis, glaucoma, or asthma

Design outcomes

Primary

Measure	Time frame
Total volume of intra-operative blood lossTimepoint: Immediate post-operative period (Postoperative day- 0)	—

Secondary

Measure	Time frame
Duration of hospital stayTimepoint: At the time of discharge;Duration of surgeryTimepoint: Immediate post-operative period (Postoperative day- 0);Fall in serum hemoglobin levelTimepoint: The next day after surgery (Postoperative day 1);Incidence of intra-operative hypotensionTimepoint: Immediate post-operative period (Postoperative day- 0);Incidence of secondary bleedingTimepoint: At the time of discharge;Indwelling catheter timeTimepoint: At the time of discharge;Irrigation fluid amountTimepoint: At the time of discharge;Requirement of blood transfusionTimepoint: At the time of discharge;Weight of resected tissueTimepoint: Immediate post-operative period (Postoperative day- 0)	—

Measure

Time frame

Duration of hospital stayTimepoint: At the time of discharge;Duration of surgeryTimepoint: Immediate post-operative period (Postoperative day- 0);Fall in serum hemoglobin levelTimepoint: The next day after surgery (Postoperative day 1);Incidence of intra-operative hypotensionTimepoint: Immediate post-operative period (Postoperative day- 0);Incidence of secondary bleedingTimepoint: At the time of discharge;Indwelling catheter timeTimepoint: At the time of discharge;Irrigation fluid amountTimepoint: At the time of discharge;Requirement of blood transfusionTimepoint: At the time of discharge;Weight of resected tissueTimepoint: Immediate post-operative period (Postoperative day- 0)

—

Countries

India

Contacts

Public ContactG Rohith

All India Institute of Medical Sciences, (AIIMS) Bhubaneswar

urol_manoj@aiimsbhubaneswar.edu.in7894453494

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026